AKBA Akebia Therapeutics Inc.

$AKBA I told Butler, he should have released Vocal results before ASN regardless this looks to be the flush out bottom. If Butler was any smart, he would authorize a buyback of shares at these low prices or just sell the company in a hostile takeover offer. He is clearly unfit to lead a potential big pharma company. The several items that could have been done differently, leading to akba share upside is mounting. He needs to shape up fast or get out of the way. This is absolutely ridiculous.

$AKBA tomorrow marks the start of 2026 ASN with Thurs the first prali poster presentation and friday near noon is the big Vafseo presentation on voice results. The timing of that vafseo voice trial presentation is the most coveted time slot and will be filled with big pharma and nephro eyes. Dr Block as usual is bound to have a fantastic presentation. Overall akba has 7 posters/talks and NJMC has another Vafseo talk, so 8 total, akba has one of the, if not largest presence at ASN. Good luck to all the honest investors in this stock.

$AKBA Butler has to be replaced quickly. Find someone competent that willing to take a modest salary and give them substantial upside potential. Sad this leach is the only one prospering

$AKBA I really don’t understand this valuation. The market seems to be pricing in every possible negative while completely ignoring the positives and long-term potential. Sure, there are risks, but does this level of pessimism really make sense? It feels extremely undervalued to me.

$AKBA another drop? I’still have an .80’s average. The last time I had a .60 average I think I tripled my money and that was before the FDA approved V. This medicine isn’t going away it simply works. Somebody is going to make a fortune on it. Who that winds up being is anyone’s guess. A buyout or AKBA that’s above my pay grade. I’m just along for the ride. GL don’t let the short posts bother you. I would love to have a tasty .50 average for the next ride up. Not sure if I can afford to get it that low if it drops again. I’m not Worried about it. Waiting on a reverse thrombosis procedure on my Iliac hopefully today. Call me a liar but I don’t worry about money anymore. The stock will take care of itself. GL bend a knee for those who can’t.

$AKBA MERGER & ACQUISITION IMMINENT? 1,2,3,6,7,8,9,10 are all ”yes.” 4 is “likely.“ 5 is ”don’t know.” Good luck to all of our honest investors.

$AKBA F*CK THE GREEDY SHORTS FOR LYING & MANIPULATING SENTIMENT SO AS TO EFFECTUATE THE THEFT OF SHARES FROM HONEST INVESTORS & TO HARM OR KILL THE INNOCENT & CHRONICALLY ILL BY STALLING & THWARTING LIFE BETTERING & SAVING DRUGS FROM REACHING THE MARKET. FILTHY SCUM.

$AKBA I expect a filing shortly requesting a R/S vote with the SEC. This time the chance of it not passing is virtually zero. That is great news for JB . He can continue to run his for his profit only company. Under the new law, a reverse stock split only requires a majority of the votes actually cast at the meeting, rather than a majority of all outstanding shares eligible to vote. In 2023, Akebia actually had far more "For" votes than "Against" votes (77.9M vs 57M), but failed under the old rules because unvoted shares counted as "No" votes. Under today's rules, that exact same vote layout would have successfully passed.

$AKBA I am PRAYING for a hostile takeover that gets Butler out of the picture. The acquiring company could basically use AKBA's current balance sheets to offset the acquisition of AKBA. The news that Butler is out would send this stock price up. Putting V into the hands of a competent company with the infrastructure in place to better market V would send the stock price up. A hostile takeover would be a win for shareholders! Especially if it happens before Butler is allowed to sink this back down to .25 cents.

$AKBA During the last 4 years the SP has moved from $2.85 to $0.71 - a loss of 75% shareholder value. Hasn’t been a straight line but if you held the stock 48 months ago and still hold it today that is the bottom line. Over the last 4 years Butler has received nearly $6M in cash compensation, $2.7m of which has been performance bonuses! This is just cash. Does not include stock awards. None of the incentive milestones in any of these 4 years has been tied to stock performance. Sure, operational milestones can be expected to support a higher stock price but often they do not. In our case substitute never for often. Most if not all his personal award objectives are things you would expect a vp or director to be tied to. What’s worse is that in many cases these objectives were not met. Percentage payouts exceeded percentage of achievement. Here’s the point. 1) Don’t expect the BoD to do anything for shareholders. They are owned by Butler. 2) Dont expect Butler to do anything for us either

$AKBA average at 1.50. Not sure to sell at a loss or to wait it out and see what happens. Biggest mistake investing in this shit

$AKBA I’VE GOT TIME. I’LL WAIT. (1)VOICE trial’s initial analysis demonstrated overwhelming statistical evidence of improved safety outcomes … Vafseo v. ESA. US Renal Care will present results at Amer. Society of Neph. Kidney Week, Oct. 21-25; (2)VOCAL’s data marked as complete, signaling data review underway as of Sept. 3rd. Results Nov. 2026; (3)AKB-9090 (Acute Kidney Injury), 1st patient dosed April 13th. Phase 1 top line data, early 2027; (4)AKB-097 (Ebribafsup), 1st patient dosed Sept. 14th. Phase 2 basket trial data in 2027; (5)Praliciguat (FSGS), Phase 2 Randomized, Double Blind … completed June 30, 2027; (6)Kidney Care Access Protection Act (KCAPA) H.R. 644. EOY 2026; (7)Q3 Nov. 10th, Q4 Feb. 25, 2027 (reports anticipated). (In very beginning of June, Davita rolled out village wide Vafseo 3Xs weekly dosing protocol). Good luck honest investors.

$AKBA For Akebia Therapeutics (AKBA), the SEC filing confirms that the BlackRock loan covenant is an OR, not an AND. Akebia must either maintain at least $15 million in cash and cash equivalents or generate $150 million in consolidated revenue over the trailing 12 months. The test is measured at the end of each fiscal month, so the company does not need to meet both thresholds simultaneously. Exact wording from the SEC filing: "The financial covenants under the BlackRock Credit Agreement require us to either (i) maintain cash and cash equivalents, measured as of the last day of each fiscal month, greater than or equal to $15.0 million or (ii) earn consolidated revenue, measured as of the last day of each fiscal month for the trailing twelve-month period, of $150.0 million." Source: SEC Form 10-Q, page 55: https://www.sec.gov/Archives/edgar/data/1517022/000151702226000051/akba-20260630.htm So no worries with this loan

$AKBA After tomorrow's close under 1.00, I say FICKT DICH to you MOFO SHORTS and hope you all drop dead by this time next year when AKBA= > $10 pps. Fickt euch alle. Akebia Therapeutics (AKBA) will trigger a standard Nasdaq minimum bid price deficiency notice once it completes its 30th consecutive business day closing below $1.00. • No Immediate Delisting: Receiving the notice does not mean immediate delisting. • 180-Day Grace Period: Nasdaq will grant Akebia an initial 180 calendar days to regain compliance. • Regaining Compliance: To resolve the deficiency, the stock's closing bid price must reach $1.00 or higher for at least 10 consecutive business days during this window. • Potential Second Extension: Because AKBA trades on the Nasdaq Capital Market, it may be eligible for an additional 180-day extension if it meets other financial listing criteria.

$AKBA This news will happen Q4 as well. Don’t let lying shorts get your shares on the cheap. DaVita is about to come in heavy and TDAPA announcement coming.

$AKBA for me, feels like capitulation. One last flust to finish with all stop losses at .60, .55 and .50 and we go up again

$AKBA Amgen has around $14 B Cash on hand , surely they could spare a couple of billion, to put us lot out of our misery 🤔

$AKBA Butler is such a terrible CEO that I wouldn't be surprised if he is trying to play hardball with Blackrock while trying to negotiate their deal and they are punishing Akebia by shorting the crap out of the stock. They are so big that they could care less about their $50 million financing. I blame all that is wrong with Akebia squarely on John Butler

$AKBA Looking back at March 2025, when AKBA was trading around $3, management chose to execute an ATM offering at roughly $2 per share, raising $50 million by issuing 25 million shares at a massive discount. In hindsight, maybe the CFO had a better understanding of the company's actual value than the market did. The company benefited from the capital raise, while shareholders absorbed the dilution. I believe the stock could magically reach $2 again by late 2027, only for the company to need more cash and dilute shareholders again at $1.20 per share. AKBA's track record has been absolutely hostile to shareholder value. At this point, pursuing the NDD indication and directing capital toward it, rather than abandoning it and focusing elsewhere, might actually have delivered better long-term shareholder value.

$AKBA really bad investment. Nothing left but hope. If they would have been profitable it would have never gone down this much. People invested money to see a product make money and all the income is going to the pockets of the people thst work for this company and other products. Shareholders get nothing.